Drug Lice Treatment Recalled Due to Manufacturing Practice Violations
Neogen Corporation has voluntarily recalled LICEOUT liquid lice treatment due to manufacturing practice violations. The recall affects 8,328 jugs distributed to institutions.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II voluntary recall due to manufacturing practice violations with no reported illnesses or injuries. The recall is precautionary and addresses process compliance issues rather than a specific identified product hazard.
Plain-English summary
Neogen Corporation has voluntarily recalled LICEOUT, a liquid lice treatment for human use, due to Current Good Manufacturing Practices (CGMP) violations. The recall includes 8,328 jugs distributed through Bob Barker Company, Inc., which supplies institutional facilities.
The Food and Drug Administration classified this as a Class II recall. The recall was initiated on October 8, 2024, and is ongoing.
Affected product includes specific lot numbers (LO09530, LO13412, LO10263, LO11303, LO12153, LO12483, LO13183, LO106024, LO108624, and LO110224) with expiration dates ranging from November 3, 2024, through April 11, 2026. Institutions that received this product should not use it and should contact Neogen Corporation or the FDA for information regarding the recall and available alternatives.
The recalled product
- Product
- LICEOUT, Liquid Lice Treatment for Human Use, Contents: 128 FL OZ. (3785.4 mL mL) per jug, Distributed By: Bob Barker Company, Inc., 7925 Purfoy Road, Fuquay-Varina, NC 27526. NDC: 53247-124-02
- Manufacturer
- Neogen Corporation
- Category
- Drug — Topical Lice Treatment
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot
- expiry: LO09530
- exp 11/3/2024
- LO13412
- exp 12/7/2024
- LO10263
- exp 1/26/2025
- LO11303
- exp 5/10/2025
- LO12153
- exp 8/3/2025
- LO12483
- exp 9/5/2025
- LO13183
- exp 11/14/2025
- LO106024
- exp 2/29/2026
- LO108624
- exp 3/26/2026
- LO110224
Distribution
Distribution scope not specified by the agency.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27